Schonfeld Strategic Advisors’s Burning Rock Biotech BNR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,806	Closed	-$557K	–	2152
2023 Q1	$557K	Buy	19,806 +8,255	+71%	+$247K	0.01%	1139
2022 Q4	$260K	Buy	11,551 +538	+5%	+$12.3K	﹤0.01%	1862
2022 Q3	$264K	Buy	+11,013	New	+$355K	﹤0.01%	2166
2021 Q2	–	Sell	-1,260	Closed	-$339K	–	1951
2021 Q1	$339K	Sell	1,260 -1,240	-50%	-$377K	﹤0.01%	1290
2020 Q4	$578K	Buy	+2,500	New	+$671K	0.01%	996

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Schonfeld Strategic Advisors's BNR Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of Burning Rock Biotech (BNR) in Q2 2023, closing a stake of 19,806 shares — an estimated $557K sold.

Schonfeld Strategic Advisors first reported a position in BNR in Q4 2020 and held it in 5 quarters. The position peaked at $578K in Q4 2020. 32 funds tracked by Wall St. Rank hold BNR as of Q2 2023.

Schonfeld Strategic Advisors reported no remaining Burning Rock Biotech position as of Q2 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 19,806 Burning Rock Biotech shares in Q2 2023, an estimated $557K.
Schonfeld Strategic Advisors first reported a position in Burning Rock Biotech in Q4 2020 and held it in 5 quarters.
Schonfeld Strategic Advisors's Burning Rock Biotech position peaked at $578K in Q4 2020.
32 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.